Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | ING2 | Q9H160 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | TIMP3 | P35625 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28012117 | 0.97 | TSHR (0.55) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| SCHEMBL50583 | 0.97 | TSHR (0.55) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| SCHEMBL4833872 | 0.95 | TSHR (0.52) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| SCHEMBL27450647 | 0.95 | TSHR (0.52) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| SCHEMBL27579780 | 0.95 | TSHR (0.52) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| SCHEMBL27679460 | 0.95 | TSHR (0.52) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| Lithium Ion SCHEMBL28696465 | 0.84 | ALDH1A1 (0.45) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| SCHEMBL8510776 | 0.83 | LMNA (0.50) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| SCHEMBL8507889 | 0.83 | LMNA (0.50) | TSHRSMN1; SMN2LMNAALDH1A1NT5E | |
| SCHEMBL9153268 | 0.78 | SMN1; SMN2 (0.47) | TSHRSMN1; SMN2LMNAALDH1A1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270499-A1 | Process for Synthesizing Atazanavir | OXYRANE (UK) LIMITED (UK) | 2009-10-29 | — | — | US | claimed |
| WO-2009130534-A1 | PROCESS FOR SYNTHESIZING ATAZANAVIR | OXYRANE (PTY) LTD. (ZA) | 2009-10-29 | — | — | WO | claimed |
| EP-1292634-B1 | PERFLUOROSULFONIC ACID MEMBRANES, METHOD FOR THE PRODUCTION AND USE THEREOF FOR FUEL CELLS | FUMA TECH GES FUER FUNKTIONELL (DE) | 2005-12-07 | — | — | EP | claimed |
| US-9023553-B2 | Multilayered composite proton exchange membrane and a process for manufacturing the same | CHEMSULTANTS INTERNATIONAL, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-7973109-B2 | Crosslinked type layered metal phosphonate compound, production process therefor, non-crosslinked type layered metal phosphonate compound, production process therefor, as well as stock solution | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | OXYRANE (UK) LIMITED (UK) | 2009-10-29 | — | — | US | disclosed |
| WO-2009130534-A1 | PROCESS FOR SYNTHESIZING ATAZANAVIR | OXYRANE (PTY) LTD. (ZA) | 2009-10-29 | — | — | WO | disclosed |
| US-20090093607-A1 | Crosslinked type layered metal phosphonate compound, production process therefor, non-crosslinked type layered metal phosphonate compound, production process therefor, as well as stock solution | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2009-04-09 | — | — | US | disclosed |
| WO-2005006474-A1 | HIGH TEMPERATURE PROTON EXCHANGE MEMBRANE USING IONOMER/SOILD PROTON CONDUCTOR, PREPARATION METHOD THEREOF AND FUEL CELL CONTAINING THE SAME | SOGANG UNIVERSITY (KR) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093607-A1 | Crosslinked type layered metal phosphonate compound, production process therefor, non-crosslinked type layered metal phosphonate compound, production process therefor, as well as stock solution | WEE1, WEE2, PPIP5K2 | TSHR 4495/4885SMN1; SMN2 4755/4885LMNA 4429/4885 |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | SAMHD1, TYMS, COASY | TSHR 3367/4885SMN1; SMN2 4559/4885LMNA 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.